Trademarkia Logo

Canada

C$
Trademark Search in Canada
MORPHOMER

View On IC.GC.CA

MORPHOMER
APPROVED

on 28 May 2025

Last Applicant/ Owned by

AC Immune SA

EPFL Innovation ParkBuilding BCH-1015 Lausanne,

CH

Serial Number

1987267 filed on 26th Sept 2019

Correspondent Address

GOWLING WLG (CANADA) LLP

1 PLACE VILLE MARIE37TH FLOOR/37E ETAGEMONTREAL

QUÉBEC

CA

H3B3P4

MORPHOMER

Trademark usage description

diagnostic biomarkers for in vitro testing for scientific use, biological assays and kits for use in fields of biological and diagnostic testing for i Read More

Classification Information

Class [001]
Diagnostic biomarkers for in vitro testing for scientific use, biological assays and kits for use in fields of biological and diagnostic testing for industrial, scientific and research use, laboratory assay kits, chemical reagents for use in genetic research, diagnostic reagents for scientific research use for detecting neurodegenerative diseases, neurological, immunological diseases and inflammatory diseases, active chemical ingredients for use in the manufacture of pharmaceuticals, none of the foregoing being in relation to or for antibodies.

Classification kind code

11

Class [005]
Pharmaceutical preparations for the diagnosis, prevention and treatment of neurological and neurodegenerative diseases, pharmaceutical preparations for the diagnosis, prevention and treatment of immunologic diseases, pharmaceutical preparations for the diagnosis, prevention and treatment of inflammatory diseases, biological preparations made from living tissues for use in immunotherapy, diagnostic reagents for medical purposes, clinical diagnostic reagents, diagnostic biomarker reagents for medical purposes, diagnostic chemical reagents for medical purposes, diagnostic reagents and agents for medical diagnostic use, diagnostic test reagents for medical purposes, medical diagnostic assay kits comprised of medical diagnostic reagents and assays for detecting autoimmune diseases, medical diagnostic assay kits comprised of medical diagnostic reagents and assays for detecting neurological diseases, namely, neurodegenerative and neurological diseases, veterinary diagnostic reagents, clinical diagnostic reagents, diagnostic chemical reagents for medical purposes, diagnostic biomarker reagents for medical purposes, diagnostic reagents and contrast media for medical purposes, imaging agents for magnetic resonance imaging (MRI), radio-isotope markers for diagnostic use, medical imaging contrast media for use with medical imaging equipment, none of the foregoing being in relation to or for antibodies.

Classification kind code

11

Class [042]
Scientific and technological services, namely clinical trials, biomedical engineering, chemical engineering, engineering in the field of immunopharmaceuticals, custom design and development of chemical reagents and biochemical assays, design and development of medical testing and analysis methods in the field of immunology, scientific research relating to the diagnosis and treatment of neurodegenerative diseases and disorders, biochemical research, research and development in the fields of assays, selection, screening, testing, imaging and diagnostics using electrochemiluminescence, research in the field of biochemistry, scientific research in the field of pharmacology, pharmaceuticals, and biochemistry, neurological research services, research and development services in the field of pharmaceutical preparations for the diagnosis and treatment of neurodegenerative and neurological diseases and disorders, research and development services in the field of pharmaceutical preparations for the diagnosis and treatment of immunological diseases and disorders, research and development services in the field of pharmaceutical preparations for the diagnosis and treatment of inflammatory diseases and disorders, platform as a service (PAAS) featuring computer software platforms for searching structured and unstructured data for clinical data analytics related to diagnostic reagents for medical purposes, biochemical assays, and the diagnosis and treatment of neurodegenerative diseases and disorders, platform as a service (PAAS) featuring computer software platforms for searching, retrieving, and sharing of information for use in the diagnosis and treatment of neurodegenerative and neurological diseases and disorders, providing medical and scientific research information in the fields of biotechnology, chemistry, pharmacy, molecular science, immunotherapy, clinical trials, and biomedicine, biomedical research services, medical research laboratory services, chemical laboratory services, scientific research laboratories for conducting research in the field of immunotherapy and neurodegenerative and neurological diseases and disorders, chemical research services, medical research services, providing medical and scientific research information in the field of biotechnology, chemistry, pharmacy, molecular science, immunotherapy, therapeutics, diagnostics and clinical trials, consultancy in the fields of biotechnology and chemistry, development of pharmaceutical preparations and medicines for the treatment of neurological diseases, research and development services in the field of immunology, custom design and development of chemical reagents and biochemical assays, analysis in the field of molecular biology, chemical molecular analysis, product optimization, and clinical trial services to pharmaceutical industries, molecular biology advice and scientific research for third parties, research in the fields of biologic therapeutic preparations, none of the foregoing being in relation to or for antibodies.

Classification kind code

11

Mark Details

Serial Number

1987267

Mark Type

Trademark

Legal History

Action TakenStatus
Submitted for opposition 42
on 28th May 2025		Advertised
Submitted for opposition 26
on 23rd Apr 2025		Approved
Submitted for opposition 27
on 23rd Apr 2025		Approval Notice Sent
Submitted for opposition 22
on 30th Jul 2024		Search Recorded
Submitted for opposition 20
on 30th Jul 2024		Examiner's First Report
Submitted for opposition 287
on 19th May 2022		Pre-Assessment Letter Sent
Submitted for opposition 31
on 7th Oct 2019		Formalized
Submitted for opposition 1
on 27th Sept 2019		Created
Submitted for opposition 30
on 26th Sept 2019		Filed